Dexcom earnings were $930.4M for the trailing 12 months ending Mar 31, 2026, with 77.8% growth year over year. The latest DXCM earnings report on Mar 31, 2026 announced Q1 2026 earnings of $199.5M, down 25.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, DXCM reported annual earnings of $836.3M, with 45.1% growth.
DXCM past earnings growth
How has DXCM's earnings growth performed historically?
On DXCM's earnings call on Invalid Date, Dexcom (NASDAQ: DXCM) reported Q1 2026 earnings per share (EPS) of $0.52, up 92.59% year over year. Total DXCM earnings for the quarter were $199.50 million. In the same quarter last year, Dexcom's earnings per share (EPS) was $0.27.
As of the last Dexcom earnings report, Dexcom is currently profitable. Dexcom's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $930.40 million, a 73.84% increase year over year.
What was DXCM's earnings growth in the past year?
As of Dexcom's earnings date in Invalid Date, Dexcom's earnings has grown 77.78% year over year. This is 49.05 percentage points higher than the US Medical Devices industry earnings growth rate of 28.73%. DXCM earnings in the past year totalled $930.40 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.